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ABSTRACT
Despite substantial progress, infectious diseases remain important causes of ill-health and premature deaths 
in Bangladesh. Bangladesh has experienced a >90% reduction in the incidence of deaths due to childhood 
diarrhoea over the last 25 years. Further reductions can be achieved through the introduction of effective 
vaccines against rotavirus and improvements in home hygiene, quality of drinking-water, and clinical 
case management, including appropriate use of oral rehydration solution and zinc. Pneumonia is now the 
leading cause of childhood deaths in Bangladesh, and the pneumonia-specific child mortality is largely 
unchanged over the last 25 years. Reductions in mortality due to pneumonia can be achieved through 
the introduction of protein conjugate vaccines against Haemophilus influenza type b and Streptococcus pneu-
moniae, improvements in case management, including efforts to prevent delays in providing appropriate 
treatment, and the wider use of zinc. Tuberculosis is responsible for an estimated 70,000 deaths each year 
in Bangladesh. Although services for directly-observed therapy have expanded markedly, improved case 
finding and involvement of private practitioners will be important to reduce the burden of disease.
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Introduction
Vaccine-preventable diseases and other infectious 
diseases have historically been major causes of ill-
health and premature deaths in Bangladesh. Over 
the last several decades, Bangladesh has made re-
markable progress in reducing the burden of infec-
tious diseases on human health, especially in chil-
dren. Nation-wide infant mortality has decreased 
from  125  deaths  per  1,000  births  in  1978  to  65 
deaths per 1,000 births in 1999-2003 (1,2). The 
rate of mortality among children aged less than 
five years (under-five mortality) in Matlab during 
1975-1977 was 280 deaths per 1,000 births (3). This 
contrasts with a national under-five mortality rate 
of 88 in 1999-2003 (2) (Fig.).  
These marked reductions in childhood mortality 
over the last 30 years are largely due to reduction 
in mortality from infectious diseases. The four in-
terventions that appear to be most responsible for 
the decline in mortality include maternal tetanus 
toxoid vaccination (3-6), measles vaccination (7,8), 
and a reduction in diarrhoea fatalities due to oral 
rehydration solution (ORS) (9) and vitamin A cap-
sules (10,11).
Millennium Development Goal 4 (MDG 4) targets 
a reduction in under-five mortality by two-thirds 
between 1990 and 2015. The Bangladesh Demo-
graphic and Health Survey, covering the 1989-
1993 period, measured under-five mortality at 133 
Major points
•	 Overall,	rate	of	infectious	diseases,	as	a	cause	
of mortality, has declined substantially since 
1990.
•	 Mortality	due	to	diarrhoeal	disease	has	de-
clined by 90+% since 1975, but still needs to 
decrease further.
•	 Mortality	due	to	pneumonia	has	not	im-
proved substantially and needs zinc and vac-
cine programmes to bring these rates down.
•	 Tuberculosis	needs	to	be	controlled	before	
HIV/AIDS becomes prevalent.Luby SP et al. Infectious diseases and vaccine sciences
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deaths per 1,000 livebirths (12). If Bangladesh is go-
ing to meet Goal 4 of the MDGs, under-five mor-
tality needs to be reduced to less than 50 per 1,000 
livebirths by 20151* (Fig.).  
Despite substantial progress, infectious diseases 
remain important causes of ill-health and prema-
ture deaths in Bangladesh. In the Bangladesh De-
mographic and Health Survey 2004, 62% of deaths 
Diarrhoea
Trend in burden of disease 
The earliest available population-based data on 
causes of deaths among under-five children in Ban-
gladesh were collected from Matlab in 1975-1977. 
Fig. Under-ﬁve mortality rates in Bangladesh
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among under-five children in Bangladesh were 
ascribed to infectious diseases (Table 1) (2). This ac-
counts for 55 deaths per 1,000 livebirths. If we 
expect a reduction in communicable diseases to ac-
count for its proportionate share of improvement 
in child mortality, childhood mortality due to in-
fectious diseases needs to be reduced by 34 deaths 
per 1,000 livebirths, or a 38% reduction between 
2000 and 2015.  
Infectious diseases are important beyond the age-
group of children. MDG 6 has set a target that, by 
2015, we will have halted and begun to reverse 
the incidence of malaria and other major diseases. 
Tuberculosis is a major cause of adult deaths, with 
an estimated 70,000 deaths per year in Bangladesh 
(13). Deaths of adults due to tuberculosis leave chil-
dren orphaned and worsen the cycle of poverty and 
illness. There are other important multiple causes 
of morbidity and mortality due to infectious diseas-
es in Bangladesh, including visceral leishmaniasis, 
malaria, Japanese encephalitis, and other meningo-
encephalitides. However, this strategic update will 
focus on three key areas that will require substan-
tial progress to meet the MDGs; the key areas are: 
diarrhoeal diseases, pneumonia, and tuberculosis.
Table 1. Causes of death among under-ﬁve
               children in Bangladesh
1991-1993 1999-2003
Proportion
ARI=Acute respiratory infection; LBW=Low birthweight
31.2
21.1
5.1
2.3
1.8
0.3
0.3
62.1
11.7
6.5
2.8
2.2
4.1
3.6
2.3
3.2
1.6
38
88
54.6
10.1
14.9
8
6.6
3.9
1.3
3
47.8
22.4
6.3
6.6
16.8
52.1
133
63.6
Possible serious infection
ARI
Diarrhoea
Neonatal tetanus
ARI + diarrhoea
Measles
Measles with ARI or diarrhoea
Infectious subtotal
Non-infectious
Birth asphyxia
Premature/LBW
Congenital abnormality
Birth injury
Injury
Malnutrition
Undetermined
Unspeciﬁed
Other causes
Non-infectious subtotal
Under-ﬁve mortality rate
(deaths by age 5 years
per 1,000 livebirths)
Death due to infectious diseases
by age 5 years per 1,000
livebirths     
Infectious
Cause of death
•	 Mortality	due	to	diarrhoea	has	declined	by	
90% since 1980, but is still too high.
•	 Bangladesh	is	a	leader	in	ORS	knowledge	and	
practice.
•	 Use	of	zinc	for	diarrhoea	needs	to	be	scaled	up	
rapidly.
•	 Rotavirus	and	cholera	vaccines	should	be	
implemented as soon as possible and practi-
cal.  A vaccine for enterotoxigenic Escherichia 
coli is needed.
•	 Cost-effective	newer	diarrhoeal	treatments	
will become available soon—we should be 
ready to implement. 
•	 Community-level	hand-washing	and	water	
purification show great promise and need to 
be scaled up.
*The official MDG 4 set by the Government of Bangladesh is 50% according to the Poverty Reduction Strategy Paper. 
Depending on the survey used for establishing the ‘baseline’ in 1990, the target could be slightly more or less, but 50% 
is the official targetLuby SP et al. Infectious diseases and vaccine sciences
Volume 26 | Number 3 | September 2008 297
The diarrhoea-specific under-five mortality rate was 
80 deaths per 1,000 children (46.6 due to watery di-
arrhoea and 33.4 due to dysentery) (3). Since meth-
ods for verbal autopsy have changed, we compared 
the current estimates by adjusting to make these 
similar to the previous estimates. Our adjustments 
for the current data assumed that all the deaths 
attributed to diarrhoea were, in fact, due to diar-
rhoea, that 50% of deaths attributed to diarrhoea 
combined with respiratory disease were due to di-
arrhoea, and that one-third of deaths due to com-
bined measles with diarrhoea or respiratory disease 
were due to diarrhoea. With these assumptions, 
using the most recently-available national verbal 
autopsy data (1999-2003), diarrhoea accounted for 
5.4 deaths per 1,000 children (12,14). Thus, Bangla-
desh has experienced a >90% reduction in the in-
cidence of deaths due to childhood diarrhoea over 
the last 25 years.  
This remarkable progress is likely due to a combina-
tion of factors, including improvements in nutrition, 
improved microbiological quality of drinking-water, 
following the substitution of surface-water sources 
for shallow tubewells, reductions in case-fatality ra-
tio from the widespread use of oral rehydration so-
lution (ORS), and wide-scale use of measles vaccine 
and vitamin A in primary healthcare programmes. 
Nevertheless, 5.4 deaths per 1,000 births remain a 
substantial cause of childhood deaths in Bangla-
desh. Treatment of diarrhoeal disease consumes 
substantial resources, and the demand for ORS ex-
ceeds 200 million sachets annually. The increased 
prevalence of antimicrobial resistance, especially 
to Shigella species (15) and to Vibrio cholerae (16), 
threatens to complicate treatment and risks, in-
creasing case-fatality ratios of patients who present 
for treatment.
Key issues contributing to burden of 
diarrhoeal disease  
Several factors contribute to the ongoing severity 
of diarrhoeal disease in Bangladesh. First, the liv-
ing environment, including foodstuffs and sources 
of drinking-water, is heavily contaminated with 
human enteric pathogens. The underlying forces 
that drive this contamination include poverty in 
the country and the high density of population. 
Bangladesh has the highest density of population 
compared to any country in the world that is not 
a small city state (17). Population growth and loss 
of land mass from global warming and elevated 
sea levels are expected to further markedly increase 
this density (see the paper on Population in this 
volume for additional discussion on the effects of 
global warming on Bangladesh). 
Second, although there has been some improve-
ment in the nutritional status of Bangladeshi chil-
dren, malnutrition remains widespread, with 43% 
of children aged less than five years being stunted, 
that is below 2 standard deviations from the mean 
of the reference population, and 17% are severely 
stunted (18). Malnutrition increases the risk of di-
arrhoea and the risk of mortality from diarrhoeal 
disease (19-21).
A third factor that contributes importantly to 
the burden of diarrhoeal disease in Bangladesh is 
that the country provides a large natural ecologi-
cal niche for V. cholerae and enterotoxigenic E. coli 
(ETEC). Most vibrios are non-pathogenic, but some 
toxin-producing V. cholerae cause severe human 
disease. At the ICDDR,B hospital, V. cholerae causes 
20-30% of cases of severe diarrhoeal disease each 
year (22). Since V. cholerae is endemic only in a few 
geographies globally, it has not attracted the same 
attention for vaccine development and prevention 
that other important pathogens have. ETEC is also 
common and occurs throughout the developing 
world, but is difficult for most laboratories to diag-
nose; so, it commonly goes unrecognized (23,24).
A fourth factor is the universal exposure to rotavi-
rus, a serious pathogen that is disproportionately 
responsible for severe diarrhoeal illness in children 
aged less than two years. Recent analysis suggests 
that at least 38% of childhood deaths from di-
arrhoea are due to rotavirus (25). Surveillance from 
two typical upazila (subdistrict) health centres 
found that rotavirus was responsible for 13% of all 
hospital admissions of under-five children (Sid-
dique	K.	Unpublished	data).	Unlike	the	bacterial	
pathogens, the burden of rotavirus will not lessen 
even if water and sanitation improves; it is common 
in developing and industrialized countries alike.
A fifth factor contributing to the burden of diar-
rhoeal disease is the lack of proper treatment for 
many children with severe diarrhoea. Although 
most people do have access to treatment facilities, 
many families choose to seek care from village doc-
tors who do not use methods of modern treatment. 
For cholera, patients may die within a few hours, 
and there may not be time even to reach a facility 
before death.
Opportunities for reducing diarrhoeal 
mortality and morbidity
Reducing the incidence of childhood deaths from 
diarrhoeal disease should focus on three areas; (a) Luby SP et al. Infectious diseases and vaccine sciences
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enteric vaccine development and introduction, (b) 
improvements in environmental health and hy-
giene, and (c) improved case management of diar-
rhoea. The three most important enteric vaccines 
for Bangladesh are vaccines against rotavirus, V. 
cholerae, and ETEC.  
Two rotavirus vaccines have been proven to be safe 
and effective, preventing nearly all hospitaliza-
tions for rotavirus where they were tested in indus-
trialized or middle-income countries. The vaccines 
have	now	been	approved	for	use	in	the	United	
States, Europe, and several other countries (26,27). 
ICDDR,B has found that the RotaRix rotavirus vac-
cine (from GlaxoSmithKline) is safe and immuno-
genic in Bangladesh, but further evaluations of its 
protective efficacy are needed to assist policy-mak-
ers in its introduction. The Centre is also evaluating 
the RotaTeq rotavirus vaccine (from Merck). Each of 
these studies with rotavirus vaccines is being con-
ducted in collaboration with the Global Alliance 
for Vaccines and Immunization (GAVI) through its 
Rotavirus Vaccine Program and the World Health 
Organization (WHO). Other candidate vaccines, 
being developed in India and elsewhere, will likely 
be available within a few years, and their marketing 
may lower the price for effective vaccination.  
Two major issues need to be addressed in order 
for these vaccines to substantially reduce mortal-
ity due to diarrhoeal disease in Bangladesh. First, 
the health benefit from the vaccines needs to be 
evaluated. The RotaTeq and RotaRix vaccines were 
effective in wealthier countries, but their effective-
ness in poor countries with a large proportion of 
malnourished children, like Bangladesh, needs to 
be established. Factors, such as malnutrition, mal-
absorption, variation of serotypes, and the presence 
of other enteric agents might lessen the effective-
ness of these vaccines. However, the vaccines could 
have a pronounced public-health benefit here by 
improving survival and growth of children and by 
lessening the need for health services.  
Although rotavirus vaccines are estimated to be 
cost-effective in economic terms, these are still 
considered expensive compared to other vaccines 
covered by EPI. Thus, in addition to determining 
health outcomes, which are almost certain to be 
very positive, evaluation of rotavirus vaccines must 
include studies on the costing and financing me- 
chanisms, so that the Government of Bangladesh 
can make a decision regarding their use.
Another type of vaccine appropriate for Bangladesh 
is a vaccine for cholera. ICDDR,B has been evaluat-
ing cholera vaccines for over 40 years, starting with 
injectable vaccines which had been used for nearly 
100 years. Testing found these injectable vaccines 
to  be  impractical  for  public-health  programmes. 
More recently, the Centre has been working with 
vaccines given orally, and two types are being eval-
uated. One is a live-attenuated vaccine called Peru-
15 (28), and the other one is a killed oral vaccine 
similar to one licensed in Europe called Dukoral. 
Dukoral, tested in Matlab in 1985, was found to be 
safe and effective (29,30), but its high cost and logis-
tic constraints have prevented its use in Bangladesh 
so far. Results from both killed and live vaccines are 
encouraging, and both may be useful in cholera-
endemic areas such as Bangladesh. Although Peru-
15 has the advantage that it can be used as a single 
dose, its storage, requires a cold-chain. Scientists at 
the Centre hope to evaluate this vaccine for efficacy 
within the next two years. With regard to the killed 
vaccine, the efforts now are to change the formu-
lation to make it cheaper and easier to distribute. 
Although this killed vaccine will require two doses, 
it does not need to be kept cold, and it may even be 
suitable for ‘over-the-counter’ distribution. 
ETEC also causes substantial rates of severe diar-
rhoeal disease (23,24). An effective vaccine would 
be expected to reduce mortality due to childhood 
diseases, but the current stage of research suggests 
that such a vaccine is unlikely to be available soon, 
although considerable effort is being invested in 
an ETEC vaccine (31). The Bill and Melinda Gates 
Foundation has recently announced that it will 
fund development of a vaccine for ETEC, and this 
funding will hopefully speed up its development.
The second intervention which is effective in reduc-
ing diarrhoeal disease relates to improving hygiene 
and sanitation. Although many feel that improved 
sanitation implies huge infrastructural costs, and in 
the long run, it will. In the short-term, however, 
much can be accomplished in the homes and vil-
lages. ICDDR,B performed much of the pioneering 
work on the effectiveness of intensive handwash-
ing promotion on the reduction of diarrhoeal dis-
ease (32-34). A recent meta-analysis suggests that 
improved handwashing reduces the incidence of 
diarrhoea, on average, by 47% (35). However, ap-
proaches that have been quite successful in pro-
moting improved handwashing on a small scale 
have not yet been demonstrated to be effective at 
a large scale. 
Similarly, efforts to improve the quality of drinking-
water through point-of-use purification can mark-Luby SP et al. Infectious diseases and vaccine sciences
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edly reduce diarrhoea (36). Again, the approaches 
need to be demonstrated to be effective at a larger 
scale (37). Both poverty and the density of popula-
tion in Bangladesh make effective environmental 
sanitation difficult. Various approaches are being 
used in Bangladesh; however, there has been little 
critical evaluation of their effectiveness in reducing 
diarrhoeal disease. Most important will be efforts 
to change community norms through explaining 
how to effectively reduce contaminations and how 
to purify and store water. Thus, efforts to creatively 
deliver  and  assess  behaviour-change  messages  at 
scale will be critical.
The third intervention to reduce diarrhoeal mortali- 
ty is improved case management of patients with 
diarrhoea. This encompasses improving strategies 
to increase recognition of serious diarrhoea by 
mothers with appropriate home-treatment, and 
developing and diffusing appropriate clinical man-
agement of diarrhoea, including the appropriate 
use of ORS and zinc throughout the country. Ban-
gladesh benefits from a strongly-held view of the 
benefits of ORS, while its use has been slipping in 
many other countries. However, the use of unnec-
essary antibiotics is still common. As the use of zinc 
increases, it is hoped that the use of unnecessary 
antibiotics will decrease. In addition, newer thera-
pies, including some based on traditional remedies, 
and including amylase-resistant starches (using 
green bananas as a readily-available source of amy-
lase-resistant starch) appear to effectively reduce 
the duration of diarrhoea and prevent the develop-
ment of persistent diarrhoea (38). The introduction 
of zinc will be critical, and the other remedies will 
also be useful as these are validated and products 
made available.
Pneumonia
Trends in burden of disease 
Pneumonia is the leading cause of childhood 
deaths globally, accounting for two million deaths 
per year among children aged less than five years 
in 2000-2003 (39). In Matlab, the pneumonia-spe-
cific under-five mortality rate, during 1975-1977, 
was 16.8 deaths per 1,000 children (3). In the most 
recent data (1999-2003), pneumonia accounted for 
28.6 deaths per 1,000 children.† Thus, in striking 
contrast to a marked reduction in diarrhoea-specific 
mortality among Bangladeshi children, the in-
cidence  of  pneumonia-specific  child  mortality 
is largely unchanged over the last 25 years (Fig.). 
Respiratory disease now accounts for five times as 
many deaths among Bangladeshi children as diar-
rhoeal disease. If Bangladesh is going to meet the 
MDG set for under-five mortality by 2015, preven-
tion of deaths due to pneumonia must be targeted.   
Both bacteria and viruses are aetiologic agents re-
sponsible for pneumonia. The most common vi-
ruses include influenza A and B, respiratory syn-
cytial virus (RSV), and metapneumovirus (40-42). 
The bacterial causes are Streptococcus pneumoniae 
and Haemophilus influenzae type b (Hib). Although 
there is not a complete understanding of the agents 
responsible for pneumonia in each setting (urban 
vs rural and age-specific rates), the picture is be-
coming more clear. Viruses are detected more com-
monly, but the bacteria tend to cause more severe 
disease by the time they are detected (43). How-
ever, since viral infections are so much more com-
mon (by a factor of 23 when comparing influenza 
and S. pneumoniae during our urban surveillance), 
viruses are, in fact, estimated to be the most com-
mon cause of severe pneumonia (44,45). Influenza 
virus is especially associated with severe illness and 
hospitalizations of young children (45-48). Addi-
tionally, evidence from both human and animal 
studies have shown that pneumococcal infection 
is more severe, even lethal, following an influenza 
infection, suggesting the need to better understand 
the possible interactions of the two types of agents 
(49,50). 
Although paediatric pneumonia is the main issue 
with regard to MDG 4, pneumonia is also a major 
health problem for the elderly (51); however, this 
•	 Pneumonia	has	overtaken	diarrhoea	as	the	
number 1 infectious killer of children.
•	 Case	management	needs	to	improve	to	prevent	
delays within the family and by providers.
•	 Zinc	 treatment	 for	 diarrhoea	 will	 prevent	
deaths from pneumonia.
•	 Vaccines	for	H. influenzae and S. pneumoniae, 
and possibly influenza virus will save lives.
•	 The	impact	of	the	introduction	of	the	new	
pneumonia vaccines needs to be monitored.
†Since the method for classifying deaths using verbal autopsies has changed over the years, we made adjustments to 
make the different years comparable. To do this, we assumed that all deaths attributed to respiratory infection were 
due to pneumonia, that 50% of deaths attributed to diarrhoea combined with respiratory disease were due to pneumo-
nia, that one-third of deaths due to combined measles with diarrhoea or respiratory disease were due to pneumonia, 
and that one-third of deaths from possible serious infection were due to pneumoniaLuby SP et al. Infectious diseases and vaccine sciences
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has not been carefully studied in developing coun-
tries. Data from developed countries suggest that 
pneumonia is common, indicating that it is likely 
a substantial cause of disease among adults in Ban-
gladesh as well.  
Key issues contributing to burden of 
pneumonia  
Despite considerable progress in understanding the 
aetiologies and clinical management of individual 
patients with pneumonia, this understanding has 
not yet resulted in a reduction in pneumonia-spe-
cific child mortality. The cornerstone of the pub-
lic-health response to childhood respiratory disease 
has been attempting to scale up clinical case man-
agement for children with signs of pneumonia. 
For individual patients, appropriate case manage-
ment is critical, but, as illustrated by the minimal 
improvement in the burden of overall disease, this 
approach has not been effective in Bangladesh in 
lowering deaths due to pneumonia. Whether this 
limited benefit is due to lack of seeking healthcare, 
lack of access to treatment when needed, or due 
to ineffectiveness of the treatment provided is not 
that clear. Effective treatment is complicated by the 
widespread emergence of resistance to first-line an-
timicrobial agents (52,53), but it is also clear that 
parents recognize the signs of severe respiratory in-
fection at a slow pace; so, proper treatment cannot 
be sought earlier in the course of the disease.  
Two factors contribute to the increased prevalence 
of antimicrobial resistance (54,55): (a) high rates of 
antimicrobial exposure among young children due 
to pneumonia and febrile illnesses and (b) inappro-
priate (unnecessary) and inadequate (dosing) anti-
microbial exposure. One factor that could reduce 
inadequate exposure and enhance compliance 
would be a shorter course of treatment of pneu-
monia, which is under consideration (56). Another 
that could assist in reducing multiple antibiotic 
exposures per illness would be to reduce treatment 
failure. New adjuvant therapies with zinc that have 
shown promise in this regard (57) and in shorten-
ing the duration of illness should be further stud-
ied.
A  barrier  to  reducing  mortality  due  to  pneumo-
nia is the inherent difficulty in the recognition of 
disease, especially in recognizing danger signs. An 
infant with pneumonia often does not appear seri-
ously ill to parents until it is too late for the child 
to receive life-saving medical therapy. In contrast 
to diarrhoea, in which the symptoms and signs are 
obvious to parents, the signs of pneumonia may 
not be recognized. When they are recognized, care-
givers may not see them as abnormal, or they may 
delay effective treatment by changing diets first, or 
seeking help from a spiritual healer. These were bar-
riers to effective treatment for diarrhoea many years 
ago, but knowledge regarding dehydration and the 
effectiveness of ORS is now nearly universal in Ban-
gladesh. Similar knowledge regarding respiratory 
infections is needed so that the danger signs can be 
recognized earlier and care sought.
Opportunities for major impact on mortality 
due to pneumonia 
Mortality due to pneumonia can be reduced sub-
stantially if new vaccines and improved case-man-
agement strategies could be employed. The poten-
tially vaccine-preventable illnesses include those 
due to H. influenzae, S. pneumoniae, and influenza. 
Additionally, mortality due to pneumonia can be 
reduced substantially by using zinc properly. The 
vaccine for H. influenzae is the protein-conjugate 
Hib (58,59) and, for S. pneumoniae, is a similar con-
jugate pneumococcal vaccine (60,61). A Hib vac-
cine-probe study in Bangladesh demonstrated that 
the Hib vaccine reduced the incidence of pneumo-
nia by 30% and meningitis by 50% (62). Another 
trial of the Hib conjugate vaccine in the Gambia 
reduced severe pneumonia by 21% (63). A conju-
gate pneumococcal vaccine reduced the incidence 
of pneumonia by 37% and reduced documented 
pneumococcal infections (all serotypes) by 50%. 
Overall mortality was reduced by 16% in the Gam-
bian study. The conjugate pneumococcal vaccine 
has not been evaluated in settings where pneumo-
nia is a major cause of child mortality in Asia; how-
ever, the ICDDR,B study area in Dhaka is making 
preparations for this kind of study.  
Regular administration of zinc provides an aetiol-
ogy-independent  intervention  to  prevent  severe 
pneumonia, and two different strategies have both 
shown effectiveness. In one ICDDR,B study, a daily 
dose of zinc was prescribed for 14 days for each 
episode of diarrhoea. Since many children have 
repeated bouts of diarrhoea, many children in the 
intervention  villages  received  several  courses  of 
zinc. Follow-up of these children in the interven-
tion villages, along with a similar group in the con-
trol villages, revealed that rates of future episodes 
of pneumonia were reduced, and importantly, the 
overall rate of mortality was reduced by about 50% 
(64). A second ICDDR,B study in urban Dhaka ad-
ministered a weekly dose of zinc in a double-blind, 
placebo-controlled, individually-randomized trial Luby SP et al. Infectious diseases and vaccine sciences
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to determine if this would reduce rates of diarrhoea 
and pneumonia. This strategy resulted in a remark-
able >80% reduction in overall mortality (65). The 
reduction in deaths was explained by a reduction 
in pneumonia. Since zinc gives aetiology-inde-
pendent protection, one does not have to adjust 
for species or serotypes of the pathogen; however, 
the strategy for administration of zinc needs to be 
consistent. While vaccines can be given in two or 
three doses, providing prolonged protection, the 
zinc therapy needs repeated dosing and consistent 
application. We believe that this is possible with 
adequate marketing and education (66,67).    
These new strategies—the new conjugate vaccines 
and zinc—hold substantial promise to prevent 
mortality due to pneumonia, but these have not 
yet been scaled up. ICDDR,B is involved in scaling 
up zinc therapy for diarrhoea, and we will continue 
to follow its impact on prevention of severe pneu-
monia. We anticipate that the Hib vaccine will 
soon be introduced in Bangladesh, and the Centre 
has received funding to monitor the vaccines im-
pact. The pneumococcal vaccine is also available at 
below market prices, and we look to its introduc-
tion in Bangladesh. The Centre is well-placed to 
assess the impact of the introduction of conjugate 
pneumococcal vaccine and to participate in the 
evaluation of future pneumococcal vaccines that 
would protect even more children than the cur-
rently-available vaccines. 
Improvements in case management are also pos-
sible both from the standpoint of improving quali-
ty of treatment and making this treatment avail-
able to children who need it. Since most children 
who die of pneumonia do not receive standard 
care, they die at home or are brought to treatment 
facilities too late. Why is this happening? Forma-
tive research is needed to understand perceptions 
of respiratory illness and to help understand how 
to communicate danger signs of pneumonia. Since 
the symptoms may not be so obvious, or may be 
perceived to have other causes, clear health mes-
sages need to be developed which will allow par-
ents to recognize pneumonia, to help them decide 
to seek care from an adequately-trained health pro-
vider, and then to take action to avail of this care. 
Our community-based studies found that most 
children with pneumonia, who are referred to the 
hospital or clinic by the health worker, do not actu-
ally visit them. Reasons for this behaviour must be 
understood to address the constraints to accessing 
proper treatment.
Considering the huge number of children with 
pneumonia, sufficient facilities are not available 
for treating them if all who were supposed to be 
hospitalized actually visited. Thus, alternative treat-
ment strategies are needed to handle the case load. 
ICDDR,B has been evaluating a day-care model 
for patients with severe pneumonia who are re-
fused admission in the hospital for lack of space 
(ICDDR,B.	Unpublished	data).	The	information	to	
date suggests that this method is as effective as hos-
pital care. Rarely, the condition of a patient will de-
teriorate, requiring admission, but more than 98% 
are successfully treated in the day-care facility. Al-
though formal costing is needed, treatment in such 
a facility is likely to be much more cost-effective 
and acceptable when compared with a hospital.  
Moving forward  
With the availability of new vaccines, the strate-
gies with zinc, and more intensive treatment pro-
grammes, it should be possible to significantly re-
duce pneumonia by at least 50% in a short period. 
Among the interventions listed, scaling up zinc is 
currently feasible and is in the process of imple-
mentation. The routine use of Hib vaccine will 
soon commence in Bangladesh, and the success of 
this  intervention  needs  to  be  closely  monitored. 
During the introduction phase, we anticipate that 
GAVI funding will pay for the costs, but impact 
data  are  needed  to  justify  subsequent  continued 
national expenditure. We look for the pneumococ-
cal vaccine to be introduced with GAVI support 
within 12-24 months after the introduction of Hib 
vaccine, and again careful assessment of impact 
will be crucial to support continued vaccination.
Influenza vaccine is not generally being considered 
for use among children in a developing country, 
but our data suggest that this may be a powerful 
intervention if it could be introduced. Since in-
fluenza-associated infections likely predispose to 
bacterial infections, it is possible that an influenza 
vaccine may provide broader-spectrum protection 
than simply against influenza. Results of prelimi-
nary studies in which the influenza vaccine was 
given to pregnant women suggested that children 
born to these mothers had fewer respiratory infec-
tions during the first six months, perhaps by vir-
tue of placental or breastmilk antibodies from the 
mother	(ICDDR,B.	Unpublished	data).	
Tuberculosis 
The WHO has declared tuberculosis as a global 
health  emergency;  the  first  infectious  disease  to Luby SP et al. Infectious diseases and vaccine sciences
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be designated as such (68). Tuberculosis remains a 
leading cause of morbidity and mortality in devel-
oping countries, including Bangladesh. About 7% 
of all deaths in developing countries are attributed 
to tuberculosis, and it is the most common cause 
of death from a single source of infection among 
adults (69). In a recent analysis of the global bur-
den of tuberculosis, Bangladesh ranked the sixth 
highest among 212 countries in 2004 (13) having 
300,000 new cases and around 70,000 deaths annu-
ally. However, there are limited systematically-col-
lected epidemiologic data from Bangladesh. While 
directly-observed treatment, short-course (DOTS) 
is provided by the Government, often with assis-
tance from NGOs, effective control of the burden 
of disease is hampered by the fact that only 46% of 
cases are detected (70). The previous tuberculosis-
prevalence survey conducted by the National Tu-
berculosis Control Programme during 1987-1988 
estimated a prevalence of sputum-positive tubercu-
losis of 870/100,000 in the population of ≥15 years 
old. It was higher among men (1,008/100,000) 
than among women (600/100,000) and higher in 
urban  areas  (1,610/100,000)  than  in  rural  areas 
(800/100,000) (72). A recently-completed popula-
tion-based surveillance in the Matlab field area of 
ICDDR,B found a much lower prevalence of tuber-
culosis, i.e. 95/100,000 among persons aged 
≥15 years (76). The estimate for incidence from the 
WHO documents which showed an annual inci-
dence of tuberculosis in Bangladesh was estimated 
to be 229 per 100,000 (13).  
Tuberculosis occurs more frequently among low-
income populations living in over-crowded, poor 
neighbourhoods, and people with little schooling 
(77). The available data on the impact of tuber-
culosis-control measures on the prevalence of the 
disease in Bangladesh is limited (78). With the im-
pending threat of the human immunodeficiency 
virus (HIV) epidemic reaching Bangladesh (79), 
there is a risk for a substantial increase in the inci-
dence of tuberculosis. 
The prevalence of sputum-smear-positive tuber-
culosis estimated by various studies is shown in 
Table 2. The wide variations in the prevalence of 
tuberculosis are likely due to differences in survey 
methods, population, and age-groups studied and 
time periods.
There is a marked gender difference in tuberculosis, 
with men being much more commonly affected 
than women. Globally, the ratio of female-to-male 
tuberculosis cases notified is 0.47-0.67 (81). In 
2004, countries reported 1.4 million smear-posi-
tive cases in men, but only 775,000 in women (82). 
The male predominance for AFB-positive sputum 
in Bangladesh is particularly pronounced (Table 3). 
Although men may be able to produce adequate 
sputum specimens more readily than women, and 
they may also be able to access treatment facilities 
more easily, there does appear to be a real difference 
•	 Bangladesh’s	burden	of	disease	from	tuber-
culosis ranks number 6 in the world.  
•	 The	DOTS	programme	with	government	
and non-government partners provides ser-
vices.
•	 Excellent	support	from	WHO	and	GFATM	
for tuberculosis is available.
•	 Need	for	basic	data	on	the	prevalence,	inci-
dence, and risk factors to better plan control 
strategy.
•	 Need	to	include	private	providers	as	partners	
in the overall control strategy.
•	 Need	for	active	case	finding	to	increase	pro-
portion of cases detected.
•	 Paediatric	tuberculosis	is	generally	not	being	
diagnosed or treated.
Table 2. Prevalence of sputum-positive tubercu-
losis estimates in different surveys
Period Organization
Prevalence 
estimates* and 
reference
1964-1966 Directorate Gen-
eral of Health 
Services, Bangla-
desh  318 (71)
1987-1988 Directorate Gen-
eral of Health 
Services, Bangla-
desh  870 (72)
1995 BRAC 70-150 (73)
2001 Damien Founda-
tion 24 (74)
2001 ICDDR,B 95** (75)
*The estimate is per 100,000 people of ≥15 years 
of age, except for Damien Foundation where the 
corresponding age of people was ≥12 years; **Tu-
berculosis cases receiving treatment but not hav-
ing  a cough of >3 weeks at the time of the survey 
were not included. Therefore, some prevalent 
cases might have been missed. If these cases were 
included, the prevalence would be 111/100,000Luby SP et al. Infectious diseases and vaccine sciences
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in rates of the infection that is not understood. A 
relationship with other environmental hazards, 
e.g tobacco, has been established as one potential 
predisposing factor that might partially or largely 
explain the gender difference (83).
Tuberculosis affects both adults and children, but 
its diagnosis is particularly difficult in children in 
whom the signs and symptoms seem to be non-
specific. This makes the assessment of the magni-
tude of childhood tuberculosis uncertain. An esti-
mated 88 million cases of tuberculosis occurred in 
the past decade globally; of them, 15 million were 
children, and five million of them died (84). Data 
on tuberculosis among children in Bangladesh are 
limited. Of the total number of newly-detected spu-
tum-smear-positive cases reported in 2000, children 
aged less than 14 years constituted only 2%. This 
is a gross under-estimate because young children 
cannot effectively produce sputum, and sometimes 
their infection is extrapulmonary. A recent review 
of the National Tuberculosis Control Programme of 
Bangladesh has, therefore, recommended research 
on childhood tuberculosis—its diagnosis and asso-
ciation with malnutrition—as a priority (85). 
Children acquire tuberculosis from droplet infec-
tion with Mycobacterium tuberculosis spread from 
aerosol formation of sputum expectorated by 
adults with pulmonary tuberculosis. A smear-posi-
tive (presence of acid-fast bacilli, M. tuberculosis, in 
the sputum as detected by microscopy) pulmonary 
tuberculosis patient may infect 50-70% of children 
aged four years or less. However, following infec-
tion, not all children develop the disease, charac-
terized by clinical or radiological abnormalities. 
Approximately 10-30% of the infected children 
develop the disease in the 3-12 months following 
infection (86). The risk of the disease is increased by 
factors, including younger age of the child, malnu-
trition, second-hand smoke or indoor air pollution, 
or any condition that compromises immune func-
tion, i.e. measles. 
Key issues contributing to burden of tuberculosis 
Inaccurate assessment  
As noted above, assessments of the prevalence of 
tuberculosis vary widely in Bangladesh. Without a 
sound assessment of its burden, it is difficult to as-
sign appropriate priority to the problem and to as-
sess the effectiveness of interventions. For example, 
case detection for tuberculosis is calculated divid-
ing the number of persons who are treated in the 
National Tuberculosis Control Programme by the 
estimated prevalence of smear-positive tuberculo-
sis in the country. Detection of cases has increased 
from 29.2% in 1993 to 46% in 2004 (70). Clearly, 
more cases are being detected, although detection 
remains below the target of 70%. However, the un-
certainty of the underlying estimate of tuberculosis 
means that the case-detection rate could be at the 
programme target or very far below. The absence of 
data undercuts sound allocation of resources within 
the National Tuberculosis Control programme. A 
nationwide tuberculosis-prevalence survey is being 
undertaken by WHO and ICDDR,B which will pro-
vide better estimates of the burden of the disease 
and from the basis for strengthening tuberculosis-
control strategies in the country. 
The prevalence of tuberculosis is not the only 
key epidemiologic data that are lacking, we also 
do not understand the pattern of transmission in 
Bangladesh. For example, we do not understand 
why males have so much more tuberculosis than 
females or the settings where tuberculosis is most 
efficiently transmitted. Innovative efforts to reduce 
tuberculosis require better understanding of its epi-
demiology. The male predominance suggests cer-
tain risk factors or transmission mechanisms that, 
if understood, could provide intervention strate-
gies. The rapid urbanization with its increasing 
crowding will also be critical to understanding the 
patterns of tuberculosis spread.
Emerging drug resistance 
The majority of patients who are enrolled in the 
National Tuberculosis Control Programme have 
a good clinical outcome. Of patients identified in 
2003, 83% were cured, 5% died, 5% defaulted, and 
1% failed therapy.$ The few studies that have been 
Table 3. Female-male ratio of sputum smear-
positive cases in different studies 
conducted in Bangladesh
Study Year of 
study
Sputum AFB-pos-
itive female/male 
ratio and refer-
ence no.
BRAC 1992-1994 0.39 (73)
NTP 1997 0.35 (80)
Damien 
Foundation
2001 0.33 (74)
ICDDR,B  2001 0.24 (75)
AFB=Acid-fast bacilli
$A patient is considered to have failed if the signs and symptoms persist and if the sputum smear continues to be posi-
tive for five months or later after starting treatmentLuby SP et al. Infectious diseases and vaccine sciences
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conducted in Bangladesh have identified relative-
ly low levels of drug-resistant M. tuberculosis. The 
prevalence of resistance of M. tuberculosis to any 
anti-tuberculosis drug has ranged from 18.6% to 
48.4%. Multidrug-resistant tuberculosis (MDR-TB) 
defined as resistance to both isoniazid and rifam-
picin ranged from 2.0% to 5.5% (Table 4) (76). In 
addition, recent molecular typing of M. tuberculosis 
strains has identified Beijing family isolates (89). 
These isolates are highly drug-resistant and ap-
pear to represent more recent transmission within 
Dhaka. MDR-TB is associated with a death rate of 
50-80% and often with a short disease span (4-16 
weeks) from diagnosis to death. Treatment of these 
cases is also much more expensive—estimated to be 
from	US$	800	to	$10,000	in	a	developing	country.	
With an estimated 10,000 MDR-TB cases in Bangla-
desh, this will be a substantial burden to control.
Difficulties in identifying cases 
From a programmatic sense, the detection of tu-
berculosis cases is difficult. Persons should be 
screened if they have a persistent cough for more 
than three weeks, and a sputum sample should be 
tested under a microscope using acid-fast staining 
methods.** Although this system should be detect-
ing especially those patients who are most likely to 
transmit the infection, there are several constraints 
which limit its success as a public-health strategy in 
Bangladesh. The first delay in case identification is 
the delay in the patient or family recognizing that 
these symptoms require investigation. The second 
delay is in finding a clinic or a provider which can 
deal with the symptoms appropriately. The third 
delay is the competence of the laboratory in accu-
rately carrying out the test. The fourth delay may 
occur if, after diagnosis, the patient is not enrolled 
in a properly-organized DOTS programme to su-
pervise the treatment during the treatment period.   
If the system is working properly, it will identify 
persons who are most likely to transmit infection, 
but it also misses many persons who will go on to 
develop more severe disease and continue to trans-
mit their infection to others.
Tuberculosis in children  
The DOTS strategy should reduce the burden of the 
disease in adults, but it does not target children. As 
a result, there is a lack of consistent programmatic 
strategy for children, and childhood tuberculosis 
remains an under-diagnosed and neglected entity. 
In developing countries, most cases of childhood 
tuberculosis are associated with malnutrition, pov-
erty, and ignorance. Poverty not only leads to mal-
nutrition but also to over-crowded housing, poor 
ventilation, indoor air pollution, and poor hygiene 
habits, such as coughing and spitting sputum in the 
open.  
The diagnosis of tuberculosis in childhood is par-
ticularly difficult because clinical manifestations 
of symptoms in children are usually non-specific.   
Unlike	adults,	infants	and	young	children	usually	
do not develop the cavitary form of pulmonary tu-
berculosis which is easily detected by a chest X-ray 
and from which M. tuberculosis enter the bronchi to 
be expectorated in the sputum. Moreover, young 
children cannot produce sputum. Malnutrition, 
which is so common in Bangladesh, not only pre-
disposes children to tuberculosis and makes it more 
severe, but also further confounds the diagnosis of 
tuberculosis because the tuberculin skin test for tu-
berculosis (PPD) often gives a false-negative result 
in malnourished patients (90). The skin test is also 
less useful because of the BCG immunization that 
is universally given in Bangladesh. Even immuno-
competent and well-nourished children with con-
firmed tuberculosis occasionally (10%) may have a 
negative skin test (91).
There are clinical scoring systems for the diagnosis 
of childhood tuberculosis (92), but these are little 
used  by  general  practitioners  who  see  most 
sick children in Bangladesh. The sensitivity and 
specificity of the scoring systems are difficult to as-
sess.
Table 4. Drug-resistance patterns of Mycobacte-
rial tuberculosis in different studies con-
ducted in Bangladesh
Study
Resistance to 
any drug
(%)
Rates (%) of 
multiple drug 
resistance and 
reference
BSMMU	 29.7     4.9 (87)
Damien 
Foundation
18.6     2 (88)
ICDDR,B  48.4     5.5 (76)
BSMMU=Bangabandhu	Sheikh	Mujib	
Medical	University;	ICDDR,B=International	
Centre for Diarrhoeal Disease Research, 
Bangladesh
**Other common methods for the diagnosis of tuberculosis include a clinical diagnosis based on signs and symptoms 
combined with a chest X-ray.  Sputum culture is possible in Bangladesh, but is not readily available.  Culture methods 
increase sensitivity but results are not available for 4-6 weeksLuby SP et al. Infectious diseases and vaccine sciences
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Role of the private sector 
More than 80% of clinical care in suspected tuber-
culosis cases in Bangladesh is provided by the pri-
vate sector. Many general practitioners have limited 
knowledge of the necessary steps to diagnose and 
treat tuberculosis. Anti-tuberculous medications are 
available over-the-counter throughout Bangladesh. 
Patients who are misdiagnosed continue to spread the 
disease to their contacts, and patients who are incom-
pletely treated are at a high risk of developing drug re-
sistance.	Unfortunately,	only	a	few	of	those	present-
ing to private care providers, including non-graduate 
(non-licensed) private practitioners, pharmacists, 
indigenous practitioners, and graduate private prac-
titioners) were properly evaluated and referred for a 
DOTS	facility	(ICDDR,B.	Unpublished	data).			
Moving forward  
Bangladesh is at a crucial stage in the epidemic of 
tuberculosis. Considerable resources are becoming 
available through the National Tuberculosis Con-
trol Programme, and there is a good partnership 
with NGOs, including BRAC and the Damien Foun-
dation and other NGOs, including the research and 
quality control provided through ICDDR,B. The 
entire effort is being assisted with the Global Fund 
to AIDS, Tuberculosis and Malaria. The cooperative 
efforts between these groups are an encouraging 
sign, and we hope that this will bring results that 
have not been seen previously. This cooperative ef-
fort will give the DOTS strategy a major boost.  
Several critical research questions, if properly en-
gaged and answered, can translate into saving of 
hundreds of thousands of lives.   
Improved assessment  
ICDDR,B is collaborating with the Government of 
Bangladesh and WHO to update the national esti-
mate of the prevalence of tuberculosis. This is a first 
step towards improving the understanding of the 
tuberculosis problem in Bangladesh. The Centre’s 
experience in population-based surveillance, its 
surveillance sites at locations throughout the coun-
try, its laboratories which have techniques for mo-
lecular typing, and a BSL-3 environment to safely 
handle specimens provide an excellent platform to 
study key issues in the transmission of the disease.   
These studies will allow for a better understanding 
of the pathways of transmission, elucidating why 
men have so much more tuberculosis than women 
and developing new ways to identify people who 
are particularly efficient at spreading tuberculosis. 
It was clear from GIS data from Matlab that the 
prevalence of tuberculosis tended to occur in clus-
ters, and understanding this clustering would help 
in case-finding in the future.  
Emerging drug resistance 
Monitoring drug resistance will be critical to en-
sure that resistant strains are not allowed to spread. 
Such strains are now occurring in Bangladesh, but 
are not yet a major problem, except in ‘retreated’ 
cases. Although the WHO provides guidelines for 
the treatment of resistant cases, there will be a con-
tinued need to monitor the practice of the system 
to insure that the guidelines are being followed. 
Further, laboratory testing is needed to continually 
update information on resistance patterns so that 
rationale drug treatments can be used. This infor-
mation will be provided to the National Tuberculo-
sis Control Programme and WHO.  
Accelerated identification of tuberculosis cases   
Although Bangladesh has been quite effective in 
treating cases once detected, many persons who are 
infected are not being detected. According to the 
national estimates, the case-detection rates have 
been improving nationally; however, there is still 
much room for more improvement. Identifying 
cases earlier in their illness will require a combina-
tion of approaches that address the ‘delays’ men-
tioned earlier. Programmes can improve communi-
cations to alert people who have persistent cough 
to seek a test. These patients must have ready ac-
cess to the tests, and the tests performed must be 
reliable. Finally, once a patient with tuberculosis is 
identified, he/she must be able to quickly enroll in 
an approved DOTS programme. Each of these steps 
must be improved but each will require concerted 
efforts by more fully understanding the delays that 
have existed. It would seem that media commu-
nications are needed for the first and the second 
delay, but improved health services and quality-
control methods are needed for the last two. Rather 
than assuming that these interventions are appro-
priate, operations research is, however, needed to 
validate the causes and solutions for the delays.
One approach which is not currently employed 
widely in Bangladesh is contact-tracing of tuber-
culosis cases. In many other countries, family 
members and other close contacts of active cases 
are screened to determine if the infection had been 
spread to these other members. This practice is not 
commonly done in Bangladesh, partly because of 
logistic/manpower constraints and partly because Luby SP et al. Infectious diseases and vaccine sciences
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of the lack of suitable screening methods. At this 
point, only symptomatic screening can be done, 
sometimes enhanced by skin testing. We know, 
however, that these contacts could be harbouring 
the infection without showing signs of the disease. 
Only more sophisticated tests could detect these in-
cubating infections.
Improved diagnostics  
Improved diagnostic tests, especially tests that 
could identify patients with active disease before 
they begin transmitting the organism to others, 
could revolutionize the control of tuberculosis. Sci-
entists at ICDDR,B have developed a new technique 
that uses cultures of peripheral blood mononuclear 
cells and detects tuberculosis-specific antibodies in 
lymphocyte supernatant (ALS) for the diagnosis of 
active pulmonary tuberculosis in adults (93). If this 
approach could be developed into a low-cost rapid 
test, it could markedly improve the clinical man-
agement of tuberculosis. 
Working with FIND,$$ ICDDR,B is validating a 
rapid and practical DNA-based test to diagnose tu-
berculosis from sputum. This test could also speed 
the diagnosis.   
Tuberculosis in children  
Diagnosis of tuberculosis in children remains an 
enigma. The laboratory test mentioned above 
could considerably simplify this effort. Pending the 
development of such tests, validation of the scor-
ing system may offer the best opportunity to iden-
tify cases early (91). Indeed, reducing childhood tu-
berculosis may contribute importantly to meeting 
MDG 4.  
Health systems research for especially vul-
nerable groups  
Tuberculosis is not randomly distributed, and ef-
forts are needed to devote resources to those who 
are most vulnerable, including interventions to 
extend DOTS to hard-to-reach areas; strengthening 
urban DOTS; improving accessibility to DOTS by 
high-risk populations (in prison, factory workers, 
persons with HIV/AIDS, the extremely poor); and 
optimizing the role of private practitioners in the 
control of tuberculosis. 
New vaccines 
Although new vaccines are not yet available, Ban-
gladesh will be a logical site to test such vaccines 
when they do become available. For the short-run, 
the control programmes will, however, depend on 
the detection of cases, assuring that these patients 
receive adequate treatment through DOTS.
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